Breast Cancer

Latest News

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Pink ribbon for breast cancer | Image Credit: Andrey Popov - stock.adobe.com
Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

February 17th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

WWR banner
December 16th 2021

What We’re Reading: Moderna Vaccine Efficacy Reduced; Vaccine Mandate Revived; New Combo Against Breast Cancer

AJMC Staff
Two doses of the Moderna COVID-19 vaccine have reduced efficacy against the Omicron variant; a federal appeals court reinstates the Biden administration’s health care worker vaccine mandate in 26 states; a new combination therapy may reduce breast cancer progression.
Surveys Probe Biosimilars in Oncology
December 13th 2021

Surveys Probe Biosimilars in Oncology

Tony Hagen
Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.
Investigators Estimate Cost of Extending HER2-Directed Therapy With Biosimilars in British Columbia
December 8th 2021

Investigators Estimate Cost of Extending HER2-Directed Therapy With Biosimilars in British Columbia

Tony Hagen
Costs of extending human epidermal growth factor receptor 2 (HER2) therapy for patients with metastatic breast cancer were estimated in a retrospective study.
Dr Funmi Olopade
December 6th 2021

Dr Funmi Olopade Previews Her Keynote Address for SABCS

Hayden E. Klein
Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, previews her keynote address for the San Antonio Breast Cancer Symposium (SABCS).
Florida Cancer Specialists & Research Institute Breast Cancer Partnership Receives National Accreditation
October 26th 2021

Florida Cancer Specialists & Research Institute Breast Cancer Partnership Receives National Accreditation

Collaboration with community partners recognized for patient care excellence.
Dr Funmi Olopade on WISDOM: When You Ask Women to Participate, They Sign Up
October 20th 2021

Dr Funmi Olopade on WISDOM: When You Ask Women to Participate, They Sign Up

Hayden E. Klein
The WISDOM study—Women Informed to Screen Depending On Measures of risk—was launched to test a personalized approach to screening compared to annual mammograms. Funmi Olopade, MD, FACP, is a professor of Medicine and Human Genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, and a co-investigator of WISDOM. She is an expert on understanding the etiology and genomic basis of cancer progression in diverse populations and has published extensively on both genetic and non-genetic risk factors for breast cancer. She discussed overcoming early challenges of low enrollment of Black women in the study.
Newspapers.
March 30th 2021

What We're Reading: RWE Finds Pfizer, Moderna Vaccines Highly Effective; Signs of COVID-19 Surge; Lawsuit Threatens Free Preventive Care

AJMC Staff
The Pfizer and Moderna COVID-19 vaccines were shown to be 90% effective in preventing infection in a real-world setting; Biden administration urges states to pause reopening plans amid signs of COVID-19 surge; a lawsuit seeks to end the requirement that preventive services be provided free of charge to Americans.
Email being sent
March 17th 2021

What We’re Reading: COVID-19 Screening Guidance; Eli Lilly Verzenio Results; Long-Haul Symptom Improvement

AJMC Staff
The FDA issues updated guidance on the emergency use authorization (EUA) process for COVID-19 screening tools; Eli Lilly releases patient-reported outcome results for Verzenio (abemaciclib) in breast cancer; COVID-19 vaccines possibly improve long-haul symptoms among patients.
Woman having a mammogram
February 15th 2021

As Mammography Screenings Drop, Advanced Breast Cancer Cases Increase in First Months of COVID-19

Jaime Rosenberg
The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
Site Logo
February 8th 2021

A Cue-to-Action Pilot Project to Increase Screening Mammography

John R. Litaker, PhD, MSc, MMedSc Naomi Tamez, BS Wesley Durkalski, MBA Richard Taylor, PhD, MPH
A targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.
Head with missing pieces
January 19th 2021

Mental Illness May Predispose Women With Breast Cancer to Higher Mortality

Maggie L. Shaw
Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.
Alexey Aleshin, MD, Natera
January 13th 2021

Dr Alexey Aleshin Discusses Lingering Struggles in Pinpointing Biomarkers for Breast Cancer Reoccurrence

Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera, said that attention on finding biomarkers for metastatic reoccurrence needs to be directed at women with a high risk of this happening.
Multiracial graphic
January 11th 2021

Researchers Identify Possible Source of Inflammatory Response Disparity in Black, White Women With Breast Cancer

Maggie L. Shaw
A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.
Alexey Aleshin, MD, Natera
January 9th 2021

Dr Alexey Aleshin: Persistent ctDNA Is Highly Predictive of Disease Outcome

Changes in circulating tumor DNA (ctDNA) are indicative of treatment response in early-stage breast cancer, pointed out Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Knocked-over pill bottle
January 4th 2021

Risk Factors Identified for Chronic Opioid, Benzodiazepine Use After Mastectomy and Breast Reconstruction

Maggie L. Shaw
An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.
Alexey Aleshin, MD, Natera
January 1st 2021

Dr Alexey Aleshin: Chemotherapy Is Meant to Eliminate, Reduce Disease Burden

Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
December 23rd 2020

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
evidence-based oncology
December 23rd 2020

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Evidence-Based Oncology
December 23rd 2020

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Evidence-Based Oncology
December 23rd 2020

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
FDA
December 23rd 2020

MacroGenics’ Margenza Approved for Metastatic Breast Cancer

Maggie L. Shaw
The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.
Top 5 breast cancer articles
December 21st 2020

Top 5 Most-Read Breast Cancer Articles of 2020

Maggie L. Shaw
These top 5 posts from our breast cancer compendium in 2020 show that while much is known about breast cancer, much remains that can help to broaden the knowledge armamentarium.
Alexey Aleshin, MD, Natera
December 18th 2020

Dr Alexey Aleshin: I-SPY 2 Findings Show How We Can Dynamically Monitor ctDNA

Patient plasma samples from this study show residual circulating tumor DNA (ctDNA) correlates with a poor prognosis in women with early-stage breast cancer, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Pink breast cancer ribbon with figures
December 14th 2020

Uptick in Early-Stage Breast Cancer Diagnoses Seen Among Minority Women Following ACA Implementation

Maggie L. Shaw
Compared with before the Affordable Care Act (ACA), study results show there was an increase in diagnoses of early-stage breast cancer among younger vs older minority women after the act.
Alexey Aleshin, MD, Natera
December 12th 2020

Dr Alexey Aleshin Highlights the Diagnostic Benefits of ctDNA in Early-Stage Breast Cancer

Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality
December 7th 2020

Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality

Maggie L. Shaw
Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
Doctor evaluating mammography.
December 5th 2020

Social Determinants of Health May Influence Undiagnosed Breast Cancer Risk

Maggie L. Shaw
Research presented at this year’s annual meeting of the Radiological Society of North America shows the possible impact of food or housing insecurity on follow-up appointments for breast cancer.
Silhouette of pregnant woman
December 1st 2020

Fertility Preservation Linked to Uptick in Live Births Following Breast Cancer

Maggie L. Shaw
Survival after breast cancer is on the rise, thereby emphasizing the importance of discussions that focus on fertility and reproduction among younger survivors.
Puzzle-piece graphic for breast cancer gene
November 27th 2020

10-Year BRCA Testing Decreases, Study Shows

Maggie L. Shaw
Among older women with and without breast and ovarian cancers, testing for the BRCA gene dropped precipitously between 2008 and 2018.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
November 25th 2020

Dr Aditya Bardia Highlights Immuno-Oncology Developments for Patients With TNBC

Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
<1
...
34567891011
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo